Floatz logo

can1012

Ductal Carcinoma in Situ

Providence Health & ServicesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Ductal Carcinoma in Situ cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
SUFENTANYL
Zealand University Hospital
Phase 4BB
TAMOXIFEN
Northwestern University
Phase 3BB
Arimidex
Alliance for Clinical Trials in Oncology
Phase 3BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

can1012 is also rated in:

metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
lobular breast carcinoma in situDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →